Literature DB >> 29806486

Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.

Lori Dupree1, Marci DeLosSantos2, Carmen Smotherman3.   

Abstract

BACKGROUND: Risk stratification for stroke in patients with atrial fibrillation is a vital step in identifying whether antithrombotic therapy is indicated for stroke prevention in this common arrhythmia.
PURPOSE: The aim of this study was to determine adherence to guideline-directed antithrombotic therapy based on Congestive Heart Failure (1 point), Hypertension (1 point), Age (≥75 years old is 2 points and 65-74 is 1 point), Diabetes (1 point), prior Stroke (2 points), Vascular Disease (1 point), and Sex Category (1 point if female; CHA2DS2-VASc) score in patients with atrial fibrillation (AF) on hospital discharge.
METHODS: A total of 293 patients discharged from this academic medical center with a history of atrial fibrillation from June 2014 to June 2016 were enrolled. Demographic data and indicators for antithrombotic therapy based on the CHA2DS2-VASc score were recorded, and factors that affected adherence to guideline-directed therapy, such as bleeding risk, falls, and alcohol abuse, were collected and analyzed.
RESULTS: At hospital discharge, 63% of patients with AF were on appropriate antithrombotic therapy, 50% with a CHA2DS2-VASc score ≥2. The odds ratio of appropriate therapy in patients with a CHA2DS2-VASc score ≥2 was 1.17 (95% confidence interval [CI]: 0.95-1.30; P = .18). When chart documentation for reasons to withhold anticoagulation was considered as appropriate therapy, 81% of patients with AF were discharged on appropriate antithrombotic therapy with an odds ratio of 1.57 (95% CI: 1.26 -1.96, P < .0001), with bleeding and falls risk as the most common reasons to withhold anticoagulation.
CONCLUSION: Based on risk stratification of stroke through the CHA2DS2-VASc score, the majority of patients with AF were discharged from the hospital on appropriate antithrombotic therapy. Withholding anticoagulation due to falls risk should be reconsidered as a result of the known benefits of stroke prevention in atrial fibrillation.

Entities:  

Keywords:  CHA2DS2–VASc score; anticoagulation; antiplatelet therapy; atrial fibrillation < heart disease; stroke

Mesh:

Substances:

Year:  2018        PMID: 29806486     DOI: 10.1177/1074248418778804

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  3 in total

1.  A new smartphone application for integrated transmural care of atrial fibrillation, AF-EduApp: Usability and validation study.

Authors:  Lieselotte Knaepen; Michiel Delesie; Rik Theunis; Johan Vijgen; Paul Dendale; Lien Desteghe; Hein Heidbuchel
Journal:  Digit Health       Date:  2021-12-23

2.  Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra Salter; Leanne Chalmers; Luke Bereznicki; Kenneth Lee
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

3.  Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia.

Authors:  Ermiyas Endewunet; Abilo Tadesse; Aynishet Adane; Mohamed Abdulkadir
Journal:  BMC Cardiovasc Disord       Date:  2020-08-17       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.